Home
Clinical Trials
S0727 Gemcitabine Hydrochlori...

S0727 Gemcitabine Hydrochloride and Erlotinib Hydrochloride With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery

Last Updated: 2022-02-08

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1/PHASE2

Total Enrollment

134 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-03-31

Study Completion Date

2014-02-25

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This randomized phase I/II trial is studying the side effects and best dose of monoclonal antibody therapy when given together with gemcitabine hydrochloride and erlotinib hydrochloride and to see how well they work compared with giving gemcitabine hydrochloride and erlotinib hydrochloride alone as first-line therapy in treating patients with metastatic pancreatic cancer that cannot be removed by surgery. Drugs used in chemotherapy, such as gemcitabine hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Giving erlotinib hydrochloride and gemcitabine hydrochloride together with monoclonal antibody therapy may kill more tumor cells.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Gemcitabine and Erlotinib in Treating Patients With Metastatic or Recurrent Pancreatic Cancer

NCT00810719

Pancreatic Cancer

COMPLETED PHASE2

Erlotinib and Gemcitabine With or Without Panitumumab in Treating Patients With Metastatic Pancreatic Cancer

NCT00550836

Pancreatic Cancer

COMPLETED PHASE2

Erlotinib Combined With Gemcitabine in Treating Patients With Newly Diagnosed Locally Advanced or Metastatic Pancreatic Cancer or Other Solid Tumors

NCT00033241

Pancreatic Cancer Unspecified Adult Solid Tumor, Protocol Specific

COMPLETED PHASE1

Gemcitabine Hydrochloride, Dasatinib, and Erlotinib Hydrochloride in Treating Patients With Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery

NCT01660971

Metastatic Pancreatic Adenocarcinoma Recurrent Pancreatic Carcinoma Stage III Pancreatic Cancer AJCC v6 and v7 +1 more

ACTIVE_NOT_RECRUITING PHASE1

Panitumumab, Chemotherapy, and External-Beam Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot be Removed by Surgery

NCT00601627

Pancreatic Cancer

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

PRIMARY OBJECTIVES:

I. To assess the appropriate dose of IMC-A12 (cixutumumab) to use in combination with gemcitabine (gemcitabine hydrochloride) and erlotinib (erlotinib hydrochloride). (Phase I) II. To assess progression-free survival in patients with metastatic pancreatic cancer treated with IMC-A12 plus gemcitabine and erlotinib compared to those treated with gemcitabine plus erlotinib alone. (Phase II) III. To assess overall survival in each of the two treatment arms in this group of patients. (Phase II) IV. To assess the total response probability (confirmed and unconfirmed, complete and partial responses) in each of the two treatment arms in the subset of this group of patients with measurable disease. (Phase II) V. To assess the qualitative and quantitative toxicities in each of the two treatment arms in this group of patients. (Phase II)

OUTLINE: This is a multicenter, phase I, dose-escalation study of cixutumumab followed by a randomized, phase II study.

Patients are initially enrolled into the phase I portion of the study to determine the recommended phase II dose (RPTD) of cixutumumab. Once the RPTD is determined, patients are enrolled into the phase II portion of the study.

PHASE I (LIMITED INSTITUTIONS): Patients receive erlotinib hydrochloride orally (PO) once daily on days 1-28, gemcitabine hydrochloride intravenously (IV) over 30 minutes on days 1, 8, and 15, and cixutumumab IV over 60 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.

PHASE II (ALL SWOG MEMBERS): Patients are randomized to 1 of 2 treatment arms.

ARM I: Patients receive erlotinib hydrochloride, gemcitabine hydrochloride, and cixutumumab at the RPTD as in phase I.

ARM II: Patients receive erlotinib hydrochloride and gemcitabine hydrochloride as in arm I.

In both arms, treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.

Previously collected tumor tissue is obtained for gene expression analyses by RT-PCR, RNA isolation, and cDNA synthesis. Blood samples are collected periodically for correlative studies. Samples are assessed for the potential relationship between gene expression levels, germline polymorphisms, Ras and P13K mutations and progression-free survival and overall survival.

After completion of study treatment, patients are followed every 6 months for up to 3 years.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Stage IV Pancreatic Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Arm I (erlotinib, gemcitabine, cixutumumab)

Patients receive erlotinib hydrochloride PO once daily on days 1-28, gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15, and cixutumumab IV over 60 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.

Group Type EXPERIMENTAL

cixutumumab

Intervention Type BIOLOGICAL

Given IV

erlotinib hydrochloride

Intervention Type DRUG

Given PO

gemcitabine hydrochloride

Intervention Type DRUG

Given IV

Arm II (erlotinib, gemcitabine)

Patients receive erlotinib hydrochloride and gemcitabine hydrochloride as in arm I. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.

Group Type ACTIVE_COMPARATOR

erlotinib hydrochloride

Intervention Type DRUG

Given PO

gemcitabine hydrochloride

Intervention Type DRUG

Given IV

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

cixutumumab

Given IV

Intervention Type BIOLOGICAL

erlotinib hydrochloride

Given PO

Intervention Type DRUG

gemcitabine hydrochloride

Given IV

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

anti-IGF-1R recombinant monoclonal antibody IMC-A12 IMC-A12 CP-358,774 erlotinib OSI-774 dFdC difluorodeoxycytidine hydrochloride gemcitabine Gemzar

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Histologically or cytologically confirmed pancreatic adenocarcinoma

* Stage IV disease (any T, any N, M1 \[distant metastases\])
* Unresectable disease
* Histologic diagnosis based on a metastatic site must be compatible with pancreatic cancer
* Measurable and/or nonmeasurable disease
* No endocrine or neuroendocrine tumors, lymphoma of the pancreas, or ampullary cancer
* No macroscopic residual disease post-resection as the only site of disease
* No clinically significant ascites
* No known brain metastases

* Patients with neurologic signs or symptoms must undergo brain imaging studies AND studies must be negative for disease
* Zubrod performance status 0-1
* ANC ≥ 1,500/mcL
* Platelet count ≥ 100,000/mcL
* Hemoglobin ≥ 9 g/dL
* Leukocytes ≥ 3,000/mcL
* Total bilirubin normal
* SGOT or SGPT ≤ 2.5 times upper limit of normal (ULN)
* Serum creatinine ≤ 1.5 times ULN OR creatinine clearance ≥ 60 mL/min
* Fasting serum glucose \< 120 mg/dL or below the ULN

* Patients with diabetes mellitus who meet this criterion must be on a stable dietary or therapeutic regimen for this condition
* INR ≤ 1.5 and PTT ≤ 5 seconds above ULN
* Not pregnant or nursing
* Fertile patients must use effective contraception
* Willing to submit previously collected tumor tissue specimens
* No history of allergic reaction attributed to compounds of similar chemical or biological composition to anti-IGF-1R recombinant monoclonal antibody IMC-A12
* No active acute or chronic infections requiring antibiotics
* No significant ongoing cardiac problems, including any of the following:

* Myocardial infarction within the past 6 months
* Uncontrolled hypertension
* Unstable angina
* Uncontrolled arrhythmia
* Congestive heart failure
* No known HIV infection
* No other prior malignancy, except for the following:

* Adequately treated basal cell or squamous cell skin cancer
* Carcinoma in situ of the cervix
* Adequately treated stage I or II cancer from which the patient is currently in complete remission
* Any other cancer from which the patient has been disease-free for 5 years
* At least 14 days since prior surgery
* At least 28 days since prior radiotherapy for palliation to metastatic sites

* Patient must have other untreated metastatic sites that would qualify them for this protocol
* At least 6 months since prior adjuvant chemotherapy
* No prior chemotherapy, hormonal therapy, immunotherapy, or chemoradiotherapy for advanced or locally advanced pancreatic cancer, including drugs that target either EGFR or IGFR
* No plans to receive concurrent chemotherapy, hormonal therapy, radiotherapy, immunotherapy, or any other type of therapy for treatment of cancer
* No prior gemcitabine hydrochloride
* No prior chimerized or murine monoclonal antibody therapy
* No concurrent CYP3A4 inducers including, but not limited to, any of the following:

* Rifampicin
* Rifabutin
* Rifapentine
* Phenytoin
* Carbamazepine
* Phenobarbital
* Hypericum perforatum (St. John's wort)
* No concurrent CYP3A4 inhibitors including, but not limited to, any of the following:

* Atazanavir
* Clarithromycin
* Indinavir
* Itraconazole
* Ketoconazole
* Nefazodone
* Nelfinavir
* Ritonavir
* Saquinavir
* Telithromycin
* Troleandomycin
* Voriconazole
* Concurrent prophylactic low-dose coumadin or low molecular weight heparin allowed provided coagulation criteria are met
* Full-dose anticoagulation allowed provided coagulation criteria are met and are under strict control and monitoring

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Philip Philip

Role: PRINCIPAL_INVESTIGATOR

SWOG Cancer Research Network

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

NEA Baptist Memorial Hospital

Jonesboro, Arkansas, United States

Site Status

Alta Bates Summit Medical Center-Herrick Campus

Berkeley, California, United States

Site Status

Mills - Peninsula Hospitals

Burlingame, California, United States

Site Status

East Bay Radiation Oncology Center

Castro Valley, California, United States

Site Status

Eden Hospital Medical Center

Castro Valley, California, United States

Site Status

Valley Medical Oncology Consultants-Castro Valley

Castro Valley, California, United States

Site Status

City of Hope Medical Center

Duarte, California, United States

Site Status

Valley Medical Oncology Consultants-Fremont

Fremont, California, United States

Site Status

Glendale Memorial Hospital and Health Center

Glendale, California, United States

Site Status

Marin General Hospital

Greenbrae, California, United States

Site Status

Sutter Health Western Division Cancer Research Group

Greenbrae, California, United States

Site Status

University of Southern California

Los Angeles, California, United States

Site Status

Contra Costa Regional Medical Center

Martinez, California, United States

Site Status

El Camino Hospital

Mountain View, California, United States

Site Status

Highland General Hospital

Oakland, California, United States

Site Status

Alta Bates Summit Medical Center - Summit Campus

Oakland, California, United States

Site Status

Bay Area Breast Surgeons Inc

Oakland, California, United States

Site Status

Bay Area Tumor Institute

Oakland, California, United States

Site Status

Larry G Strieff MD Medical Corporation

Oakland, California, United States

Site Status

Tom K Lee Inc

Oakland, California, United States

Site Status

University of California Medical Center At Irvine-Orange Campus

Orange, California, United States

Site Status

Valley Care Health System - Pleasanton

Pleasanton, California, United States

Site Status

Valley Medical Oncology Consultants

Pleasanton, California, United States

Site Status

California Pacific Medical Center

San Francisco, California, United States

Site Status

Doctors Medical Center- JC Robinson Regional Cancer Center

San Pablo, California, United States

Site Status

Sutter Solano Medical Center

Vallejo, California, United States

Site Status

Poudre Valley Hospital

Fort Collins, Colorado, United States

Site Status

Piedmont Hospital

Atlanta, Georgia, United States

Site Status

Atlanta Regional CCOP

Atlanta, Georgia, United States

Site Status

Northside Hospital

Atlanta, Georgia, United States

Site Status

Saint Joseph's Hospital of Atlanta

Atlanta, Georgia, United States

Site Status

Well Star Cobb Hospital

Austell, Georgia, United States

Site Status

John B Amos Cancer Center

Columbus, Georgia, United States

Site Status

Dekalb Medical Center

Decatur, Georgia, United States

Site Status

Gwinnett Medical Center

Lawrenceville, Georgia, United States

Site Status

Wellstar Kennestone Hospital

Marietta, Georgia, United States

Site Status

Southern Regional Medical Center

Riverdale, Georgia, United States

Site Status

Harbin Clinic Medical Oncology and Clinical Research

Rome, Georgia, United States

Site Status

Memorial Health University Medical Center

Savannah, Georgia, United States

Site Status

Saint Joseph's-Candler Health System

Savannah, Georgia, United States

Site Status

South Georgia Medical Center

Valdosta, Georgia, United States

Site Status

Cancer Care Center of Decatur

Decatur, Illinois, United States

Site Status

Decatur Memorial Hospital

Decatur, Illinois, United States

Site Status

Crossroads Cancer Center

Effingham, Illinois, United States

Site Status

Menorah Medical Center

Overland Park, Kansas, United States

Site Status

Saint Luke's South Hospital

Overland Park, Kansas, United States

Site Status

Shawnee Mission Medical Center

Shawnee Mission, Kansas, United States

Site Status

Christus Saint Frances Cabrini Hospital

Alexandria, Louisiana, United States

Site Status

Sinai Hospital of Baltimore

Baltimore, Maryland, United States

Site Status

Boston Medical Center

Boston, Massachusetts, United States

Site Status

Bronson Battle Creek

Battle Creek, Michigan, United States

Site Status

Mecosta County Medical Center

Big Rapids, Michigan, United States

Site Status

Wayne State University

Detroit, Michigan, United States

Site Status

Grand Rapids Clinical Oncology Program

Grand Rapids, Michigan, United States

Site Status

Saint Mary's Health Care

Grand Rapids, Michigan, United States

Site Status

Spectrum Health at Butterworth Campus

Grand Rapids, Michigan, United States

Site Status

Mercy Health Partners-Mercy Campus

Muskegon, Michigan, United States

Site Status

William Beaumont Hospital

Royal Oak, Michigan, United States

Site Status

Munson Medical Center

Traverse City, Michigan, United States

Site Status

Metro Health Hospital

Wyoming, Michigan, United States

Site Status